Navigation Links
Dharma Therapeutics Shows IDDS Is Effective in Reducing Pain,,,Associated With Insertion of an Intravenous Catheter in Their Phase,,,2 Clinical Trial

Iontophoretic Drug Delivery System, dermal patch and a direct current power source with lidocaine and epinephrine (IDDS)

SEATTLE, March 20, 2007 /PRNewswire/ -- Dharma Therapeutics, Inc., ("Dharma") Seattle, WA, a transdermal drug delivery company and wholly owned subsidiary of Transcutaneous Technologies, Inc. ("TTI"), Tokyo, Japan announced that its active transdermal delivery technology, which administers lidocaine and epinephrine through the skin via a mild electric current, was safe and effective in delivering topical anesthesia in 8 minutes.

About the trial:

The trial was a Phase 2, double-blind, randomized, placebo-controlled, two-arm study evaluating the safety and effectiveness of the administration of lidocaine and epinephrine using the IDDS to provide topical anesthesia in adults undergoing a venipuncture procedure. Seventy one (71) healthy volunteer subjects ranging in age from 18 to 57 years old were treated at a single clinical site. Subjects were randomized to receive an 8 minute administration of lidocaine plus epinephrine (Treatment Arm) or epinephrine alone (Placebo-Control Arm) at the site of insertion of an intravenous catheter into the posterior surface of the subject's hand. After placement of the intravenous catheter, subjects evaluated their pain using the VAS scoring system and were asked if they would use the IDDS again. Investigators also evaluated the subjects' level of pain and whether or not IDDS treatment was acceptable to the subjects. Safety of the treatment was also monitored.

Results:

Median VAS scores were reduced by 58%, a highly significant reduction in perceived pain (p < / = 0.01). The majority of subjects in the Treatment Arm reported elimination of their pain, while only a minority of subjects in the Placebo-Control Arm reported pain elimination (p < 0.05). Thirty-four of thirty-si
'"/>




Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:12/22/2014)... Dec. 22, 2014 Apnea Sciences ( www.apneasciences.com ... in Aliso Viejo , California.  ... the tremendous growth and worldwide expansion, a new facility ... SnoreRx, the anti snore cure have exceeded our expectations ... "We are now in 23 countries and will be ...
(Date:12/22/2014)... 2014 Research and Markets ( ... "Investment Analysis of the US Medical Device ... http://photos.prnewswire.com/prnh/20130307/600769 ... device sector identifies the key trends and rationale ... and mergers and acquisitions. The study ...
(Date:12/22/2014)... Pa. and STOCKHOLM , ... (publ) (Sobi) and partner Auxilium Pharmaceuticals, Inc. today announced ... (CHMP) of the European Medicines Agency (EMA) has adopted ... clostridium histolyticum) for the treatment of adult men with ... of at least 30 degrees at the start of ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6
... Texas, Sept. 29 Luminex Corporation (Nasdaq: ... 2010 Prix Galien USA Award for its innovative xTAG® ... named Best Medical Technology at the Prix Galien USA ... 2010, at the American Museum of Natural History in ...
... asked today to make protecting the eyes from ... by increasing the prevalence of UV and eye-health ... as the Surgeon General, and in upcoming healthcare ... the Congressional Vision Caucus, provided the opening remarks ...
Cached Medicine Technology:Luminex Corporation Wins Prestigious 2010 Prix Galien USA Award 2Prevent Blindness America Issues Call-to-Action to Make UV Eye Protection a National Health Priority 2Prevent Blindness America Issues Call-to-Action to Make UV Eye Protection a National Health Priority 3
(Date:12/24/2014)... Epigenetics finds applications in a large number of ... developmental biology, and research for metabolic and genetic disorders. ... widely used techniques for the discovery and development of ... is rapidly growing worldwide. In 2012, there were 14.1 ... 32.6 million people living with cancer (within five years ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 Dr. Vu ... the expansion of his practice and med-spa with the ... practice’s growing list of cosmetic treatments and services. , ... into the skin,” says Dr. Ho. “As a result ... such as wrinkles, sun spots, discolorations or blemishes.” , ...
(Date:12/24/2014)... Mike Billings , PT, MS, CEEAA, President ... PT, MBA, GCS, Director of Professional Development to discuss ... of the Improving Medicare Post-Acute Care Transformation Act ... the Infinicast, the two leaders discuss how the IMPACT ... to standardize post-acute assessment data for quality, payment, and ...
(Date:12/24/2014)... new, injectable weight-loss drug has been approved by the ... Tuesday approved Saxenda (liraglutide) for adults who are obese ... least one weight-related health condition, such as high blood ... taking the drug, made by Novo Nordisk, should still ... noted. "Obesity is a public health concern and ...
(Date:12/24/2014)... HealthDay Reporter TUESDAY, Dec. 23, 2014 (HealthDay ... call for giving the cholesterol-lowering drugs known as statins to ... These new standards bring the association in line with the ... recommend giving low- or high-dose statins to all people at ... agree that the decision to start a statin should be ...
Breaking Medicine News(10 mins):Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Latest Episode of Infinicast Features Infinity Rehab President Discussing IMPACT Act of 2014 and Changes for Post-Acute Therapy Providers in 2015 2Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 2Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 3
... aspects of the disorder, researcher says , , SUNDAY, April ... weakness in a child with autism may point to ... means the muscles don,t get the energy they need. ... also play a role in the development of autism, ...
... save dollars, make sense , , SUNDAY, April 13 (HealthDay ... diabetes and their caregivers wondering if they,ll be able ... a misconception that these plans have to be costly ... Association says. , "Eating well and spending less ...
... allergy attacks in their tracks , , SATURDAY, April 12 ... season for millions of Americans. , With a ... limit their suffering or perhaps even avoid it altogether, ... chief of allergy and clinical immunology at the Saint Louis ...
... companionship that goes beyond caretaking, SAN FRANCISCO, ... a,new company that provides individualized care services customized ... launch its most,innovative service for providing care to ... will provide engaging one-on-one experiences for,seniors on an ...
... Scheduled for 8:30 a.m. ET, ORANGE COUNTY, Calif., ... announced today it will host a conference call on,Wednesday, ... the company,s first,quarter 2008 results. Earnings will be released ... The call may be accessed by dialing (877) 516-3365 ...
... NEW YORK, April 11 Takeda,Pharmaceutical Company Limited ... cash tender offer for all outstanding shares of ... for US$25.00 per share. The tender offer is ... subsidiary of Takeda America Holdings,Inc., which is a ...
Cached Medicine News:Health News:Muscle Weakness Found in Some Autistic Children 2Health News:Muscle Weakness Found in Some Autistic Children 3Health News:Diabetic Food Shopping That Won't Break a Budget 2Health News:Spring and Pollen Are in the Air 2Health News:Send Me An Angel(TM) Pairs Senior Citizens With Their Peers in Alternative Care 2Health News:Send Me An Angel(TM) Pairs Senior Citizens With Their Peers in Alternative Care 3Health News:Beckman Coulter Announces First Quarter 2008 Earnings to be Released on Wednesday, April 30, 2008, Before Market Opens 2Health News:Takeda Commences Cash Tender Offer for all Outstanding Shares of Millennium 2Health News:Takeda Commences Cash Tender Offer for all Outstanding Shares of Millennium 3
Disposable Microscissors: Horizontal, Curved...
Disposable Microscissors: Horizontal, Straight...
Disposable Microscissors: Vertical, 90...
Low profile, sharp-tipped scissors with a vertical cutting action. Excellent for peeling and cutting fine epiretinal membranes....
Medicine Products: